Lantheus Holdings Inc (LNTH)

Over the past six months, Lantheus's stock price has been impacted by several events. Lantheus reported stronger-than-expected Q4 2025 results, but PYLARIFY sales decreased and 2026 revenue guidance fell below analyst expectations. The FDA approved PYLARIFY TruVu and gave tentative approval for Lutetium Lu 177 Dotatate. The PDUFA date for LNTH-2501 was extended by three months. Lantheus completed the acquisition of Evergreen Theragnostics and Life Molecular Imaging and announced the planned divestiture of its legacy SPECT business. The stock price has shown mixed performance, with gains over the last 30 days and year-to-date, but a decline over the past year.

The demand for Lantheus's products and services is generally driven by medical necessity rather than strong seasonal fluctuations. While broader economic conditions can impact the overall demand for healthcare services and pharmaceuticals, there is no direct evidence to suggest inherent seasonality in the demand for its specific radiopharmaceutical or diagnostic imaging products.

Lantheus Holdings, Inc. is a radiopharmaceutical company focused on providing diagnostic and therapeutic products. Lantheus operates in the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution, and Drug Manufacturers - Specialty & Generic industries. The company's product portfolio is categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Major commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, Xenon-133, Cardiolite, Thallium and Gallium. Lantheus also has a robust pipeline, including LNTH-2501, NAV-4694, MK-6240, LNTH-2401 and LNTH-2402, LNTH-2403, LNTH-2404, and Lutetium Lu 177 Dotatate.

Lantheus is headquartered in Bedford, Massachusetts, USA, and maintains additional offices in New Jersey, Canada, Sweden, Switzerland, Germany, and the United Kingdom. The company manufactures and markets its products in the United States, primarily to hospitals, independent imaging centers, and government facilities. Internationally, it sells products through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America, and South America.

Lantheus has a renowned reputation in nuclear medicine. The company has actively worked to enhance its reputation and strategic positioning through a significant pivot towards innovative PET radiodiagnostics, divesting its legacy SPECT business to prioritize high-growth oncology and neurology segments. Recent FDA approvals and advancements in its pipeline contribute positively to its brand image as a leader in precision medicine.

Lantheus Holdings, Inc. has significant institutional ownership, with 397 institutional owners holding approximately 92.95% of the company. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Janus Henderson Group Plc, Farallon Capital Management Llc, Fmr Llc, State Street Corp, Morgan Stanley, Geode Capital Management, Llc, and Dimensional Fund Advisors Lp. Individual ownership accounts for approximately 2.1% of the shares.